{
    "nctId": "NCT00764322",
    "briefTitle": "Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen",
    "officialTitle": "Validating CYP2D6 Genotype-Guided Tamoxifen Therapy for a Multiracial U.S. Population",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Menopausal Symptoms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 501,
    "primaryOutcomeMeasure": "Endoxifen Concentrations in Participants Receiving Tamoxifen Citrate Dose of 20 mg or 40 mg Stratified by the Metabolizing CYP2D6 Genotypes",
    "eligibilityCriteria": "Inclusion:\n\nHistologically confirmed invasive carcinoma of the breast or ductal breast carcinoma in situ Has been receiving tamoxifen citrate at a dose of 20 mg/day for at least 4 months either for the treatment of invasive or non-invasive carcinoma of the breast or for breast cancer recurrence prevention\n\n* Expected duration of tamoxifen citrate treatment at least 6 months Hormone receptor status not specified Concurrent participation in non-treatment studies allowed provided it will not interfere with participation in this study Menopausal status not specified Eastern Cooperative Oncology Group (ECOG) performance status 0-2 Life expectancy \u2265 6 months Absolute Neutrophil Count (ANC) \u2265 1.0 x 10\\^9/L Platelet count \u2265 100 x 10\\^9/L Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \u2264 2.5 times Upper Limit of Normal (ULN) Total bilirubin \u2264 2.5 times ULN Creatinine clearance \u2265 50 mL/min Fertile patients must use effective contraception\n\nPRIOR CONCURRENT THERAPY:\n\n* No limitations to number of prior therapies\n* No limitations for prior radiotherapy\n* More than 14 days since prior and no other concurrent investigational agent\n\nExclusion:\n\nNot pregnant or nursing No active, serious infection or medical or psychiatric illness likely to preclude study participation No psychiatric conditions that would preclude study compliance or informed consent No history of venous thromboembolism, transient ischemic attack, or cerebral vascular accident No history of allergic reaction to tamoxifen citrate or any of its reagents No concurrent coumadin\n\nNo concurrent medications known to inhibit CYP2D6, including any of the following:\n\n* Amiodarone\n* Haloperidol\n* Indinavir\n* Ritonavir\n* Quinidine\n\nNo concurrent selective serotonin reuptake inhibitors, except the following:\n\n* Venlafaxine\n* Citalopram",
    "sex": "FEMALE",
    "minimumAge": "21 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}